drugset / Trial / NCT07469241
Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.
NaSingle-groupOpen-labelTreatment
Summary
FUTURE-3 was a prospective, multicenter, single-arm phase II study designed to explore the efficacy and safety of MRI-guided individualized chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. The primary endpoint was one-year progression-free survival rate.
Timeline
- Start
- 2026-03-10
- Primary completion
- 2028-12-31
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | — |
| Subject | Albumin-Bound Paclitaxel | Unknown | 100 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 30 mg/m2 | — |
| Subject | Paclitaxel micelles | Unknown | 100 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 200 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 200 mg | — |